CINECA IRIS Institutional Research Information System

GRANCHI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.356
AS - Asia 5.866
EU - Europa 5.844
SA - Sud America 957
AF - Africa 286
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 5
Totale 24.337
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.983
IT - Italia 2.828
SG - Singapore 1.828
CN - Cina 1.553
HK - Hong Kong 845
BR - Brasile 802
SE - Svezia 609
VN - Vietnam 495
DE - Germania 476
FR - Francia 367
BG - Bulgaria 314
GB - Regno Unito 299
CA - Canada 264
IN - India 237
FI - Finlandia 222
TR - Turchia 201
RU - Federazione Russa 180
KR - Corea 157
JP - Giappone 140
AT - Austria 133
NL - Olanda 81
UA - Ucraina 71
AR - Argentina 63
BD - Bangladesh 62
MX - Messico 57
BE - Belgio 53
IQ - Iraq 47
CI - Costa d'Avorio 45
ZA - Sudafrica 44
PL - Polonia 40
CH - Svizzera 36
ES - Italia 35
MA - Marocco 35
PK - Pakistan 31
NG - Nigeria 30
UZ - Uzbekistan 30
EG - Egitto 27
SA - Arabia Saudita 27
SN - Senegal 27
ID - Indonesia 26
EC - Ecuador 24
AU - Australia 21
CO - Colombia 20
IR - Iran 20
TW - Taiwan 20
IL - Israele 19
VE - Venezuela 19
CZ - Repubblica Ceca 16
IE - Irlanda 14
TN - Tunisia 14
DZ - Algeria 12
KE - Kenya 12
PH - Filippine 12
CL - Cile 11
MY - Malesia 11
NP - Nepal 11
AE - Emirati Arabi Uniti 10
RO - Romania 10
AZ - Azerbaigian 9
JO - Giordania 9
GH - Ghana 8
HU - Ungheria 8
LT - Lituania 8
PY - Paraguay 8
AO - Angola 7
DK - Danimarca 7
DO - Repubblica Dominicana 7
ET - Etiopia 7
JM - Giamaica 7
LB - Libano 7
OM - Oman 7
PA - Panama 7
PT - Portogallo 7
TH - Thailandia 7
TT - Trinidad e Tobago 7
QA - Qatar 6
AL - Albania 5
CR - Costa Rica 5
HN - Honduras 5
KW - Kuwait 5
KZ - Kazakistan 5
AM - Armenia 4
BY - Bielorussia 4
GR - Grecia 4
KG - Kirghizistan 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
BJ - Benin 3
CU - Cuba 3
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
LY - Libia 3
MO - Macao, regione amministrativa speciale della Cina 3
PE - Perù 3
RS - Serbia 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
EU - Europa 2
GA - Gabon 2
Totale 24.292
Salva come PNG Salva come JPEG
Città #
Ashburn 1.129
Singapore 1.055
Woodbridge 956
Serra 954
Fairfield 828
Hong Kong 827
Dallas 762
San Jose 638
Ann Arbor 623
Houston 597
Chandler 575
Santa Clara 516
Seattle 356
Shanghai 329
Beijing 316
Sofia 314
Wilmington 289
Cambridge 287
New York 245
Milan 225
Los Angeles 203
Hefei 197
Boardman 181
Princeton 160
Pisa 158
Ottawa 153
Council Bluffs 139
Lauterbourg 127
Seoul 123
Florence 120
Ho Chi Minh City 116
Vienna 114
Lawrence 113
Tokyo 112
Helsinki 110
Medford 106
Izmir 99
Munich 99
Rome 93
London 92
Marseille 88
Hanoi 84
Nanjing 84
Des Moines 80
Dearborn 76
Jacksonville 68
Redondo Beach 68
Istanbul 64
Redwood City 64
Boulder 62
São Paulo 60
Dong Ket 59
Lucca 57
Frankfurt am Main 54
Livorno 53
Abidjan 44
Buffalo 41
Columbus 41
Chicago 40
Orem 40
Hyderabad 39
Ogden 39
San Diego 38
The Dalles 35
Turku 34
Lagos 30
Nanchang 30
Belo Horizonte 29
Mumbai 28
San Francisco 28
Bologna 27
Brussels 27
Dakar 27
Rio de Janeiro 27
Amsterdam 26
Chennai 25
Kunming 23
Mexico City 22
Warsaw 22
Washington 22
Düsseldorf 21
Tashkent 21
Baltimore 20
Manchester 20
Nuremberg 20
Zurich 20
Baghdad 19
Casablanca 19
Denver 19
Hangzhou 19
Montreal 19
Phoenix 19
Toronto 19
Ankara 18
Guangzhou 18
Vicopisano 18
Dhaka 17
Johannesburg 17
Louvain-la-Neuve 17
Pessac 17
Totale 16.618
Salva come PNG Salva come JPEG
Nome #
COMPOSTO INIBITORE DELL’ENZIMA LATTATO DEIDROGENASI (LDH) E COMPOSIZIONE FARMACEUTICA CHE COMPRENDE TALE COMPOSTO 357
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 329
Glycoconjugated metal complexes as cancer diagnostic and therapeutic agents 312
GLUT1 and LOX inhibitors as perspective anticancer agents tackling glucose avidity and ECM remodeling in tumors 270
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 265
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 260
New activators of SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies 245
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 237
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 234
Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents 229
Sonde diagnostiche per evidenziare all’infrarosso cellule e tessuti affetti da condizioni patologiche o metaboliche 229
Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche 221
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 220
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 219
Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors 214
Glucose transporters: production, crystallization and inhibition 213
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 213
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor 213
Rational Development of MAGL Inhibitors 210
Diagnostic probes to detect cells and tissues afflicted with a pathological or metabolic condition by means of infrared spectroscopy 208
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death 206
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 206
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 203
Historical perspective of tumor glycolysis: a century with Otto Warburg 200
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 199
Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials 199
Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors 198
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 198
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 197
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 195
Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer 195
Identification of new FYN kinase inhibitors using a FLAP-based approach 194
Reactive Oxygen Species Synergize to Potently and Selectively Induce Cancer Cell Death 194
Risks and Benefits Related to Alimentary Exposure to Xenoestrogens 193
Anticancer agents interacting with membrane glucose transporters 192
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 190
An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade 190
Phenylethanoid glycosides from Cistanche phelypaea acting as monoacylglycerol lipase inhibitors 190
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer 190
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors 189
Functionalized aliphatic polyketones with germicide activity 189
Estrogen receptor ligands: a patent review update 187
ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism 187
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 185
Anticancer Agents That Counteract Tumor Glycolysis 183
Cyclic Ketoximes as Estrogen Receptorβ Selective Agonists 183
Design, Synthesis, and Evaluation of GLUT Inhibitors 183
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes 182
An update on therapeutic opportunities offered by cancer glycolytic metabolism 182
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 180
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 179
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia 179
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways 179
Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer 177
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives 174
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 174
Nuovi agenti antivirali a struttura N-idrossiindrol-carbossamidica 173
Natural compounds as inhibitors of lactate dehydrogenase 173
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 172
Clerodanes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL) 171
Salicylketoximes that target glucose transporter 1 restrict energy supply to lung cancer cells 171
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors 170
Salicylketoximes as inhibitors of Glucose Transporters 170
Preclinical emergence of novel lactate dehydrogenase inhibitors as potent antitumor agents in hypoxic models of pancreatic cancer: molecular mechanisms underlying their synergistic interaction with gemcitabine 168
VenomPred 2.0: A Novel In Silico Platform for an Extended and Human Interpretable Toxicological Profiling of Small Molecules 166
Biphenyl-Derivatives Possessing Tertiary Amino Groups as ß-Secretase (BACE1) Inhibitors 166
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies 166
Bioactive heterocycles containing endocyclic N-hydroxy groups 165
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. 165
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 164
BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides 163
Nuovi inibitori reversibili della monoacilglicerolo lipasi (MAGL) quali potenziali agenti antitumorali, antiinfiammatori e neuroprotettivi. 163
N-Hydoxyindoles: novel, selective, and efficient inhibitors of isoform 5 of human lactate dehydrogenase (hLDH-5) 162
Effect of Tumor Relevant Acidic Environment in the Interaction of a N-hydroxyindole-2-Carboxylic Derivative with the Phospholipid Bilayer 162
Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors 160
Small-molecule inhibitors of human LDH5 160
Abstract 3082: Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2 158
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours 156
Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing 155
First-of-its-kind STARD 3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent 155
Application of MM-PBSA methods in virtual screening 155
Synergistic Interaction of Novel Lactate Dehydrogenase Inhibitors with Gemcitabine in Hypoxic Models of Pancreatic Cancer 154
Constituents of Polygala flavescens ssp. flavescens and their activity as inhibitors of human lactate dehydrogenase 154
AGENTI TERAPEUTICI IN GRADO DI RIDURRE LA PRODUZIONE CELLULARE DI ACIDO LATTICO E COMPOSIZIONI FARMACEUTICHE CHE COMPRENDONO TALI COMPOSTI 153
A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017) 152
Activators of Sirtuin-1 and their Involvement in Cardioprotection 152
Carbazole-containing arylcarboxamides as BACE1 inhibitors 151
Sirtuin 1-Activating Compounds: Discovery of a Class of Thiazole-Based Derivatives 150
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present) 149
Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma 148
The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review 148
Development and validation of a docking-based virtual screening platform for the identification of new lactate dehydrogenase inhibitors 148
New phenylethanoid glycosides from Cistanche phelypaea and their activity as inhibitors of monoacylglycerol lipase (MAGL) 148
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 146
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds 146
First-in-Class Dual Targeting Compounds for the Management of Seizures in Glucose Transporter Type 1 Deficiency Syndrome 144
Inhibitors of lactate dehydrogenase (hLDH5) from Polygala flavescens subsp. flavescens 144
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 142
Lactate dehydrogenase A (LDH-A) inhibitors as starvation agents against invasive hypoxic tumours 142
New diterpenes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL) 142
Totale 18.641
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.811
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021307 0 0 0 0 0 0 0 0 0 0 100 207
2021/20221.750 85 114 57 103 227 272 72 100 61 72 94 493
2022/20232.096 230 288 166 173 230 279 33 153 348 19 142 35
2023/20241.526 128 121 126 96 201 251 112 67 31 54 114 225
2024/20255.163 69 181 147 279 415 496 399 262 493 599 621 1.202
2025/20266.415 370 814 913 687 602 523 989 331 517 495 174 0
Totale 24.793